Business
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe)
About this update from Amgen Inc.
[{"type":"text","content":"THOUSAND OAKS, Calif., May 2, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present new long-term data of Aimovig® (erenumab-aooe) across the migraine spectrum at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia. Data from a one-year open-label extension (OLE) trial following a three-month double blind study in patients with chronic migraine (15 or more headache days per month) showed sustained efficacy and safety in this patient population, including a potential for conversion to episodic migraine (4-14 headache days a month). Additionally, one-year results of the Phase 3 STRIVE study reinforced the sustained efficacy and safety profile of Aimovig in patients with episodic migraine, including patients who had tried and failed prior preventive treatments. \nMigraine is a highly debilitating disease that has a profound and limiting impact on peoples' lives, including time spent with family and friends, or at work.2,3 Aimovig, co-commercialized in the U.S. by Amgen and Novartis, is the first and only FDA-approved treatment that prevents migraine by targeting the calcitonin gene-related peptide (CGRP) receptor. It is self-administered once monthly via the SureClick® autoinjector, does not require a loading dose and is easy to use.1\n\"We are pleased to see new efficacy and safety results for Aimovig, which was the first CGRP therapy approved by the FDA in May 2018 and has the longest post-approval treatment experience of any CGRP therapy,\" said David M. Reese, M.D., executive vice president of Research and Development at Amgen. \"These long-term results further establish the benefit of Aimovig across the spectrum of patients with migraine.\"\nData in Chronic MigraineAn exploratory analysis of one-year OLE data from the pivotal study evaluating the efficacy and safety of Aimovig in chronic migraine prevention assessed the conversion rate from chronic to episodic migraine.4 The results at 52 weeks showed more than two-thirds of patients with chronic migraine on Aimovig converted to episodic migraine by the last dose received. Patients converting to episodic migraine showed a reduction of 11 monthly migraine days (MMD) at week 52, from a baseline of 17 MMD. Both doses had high conversion rates, with the Aimovig 140 mg dose numerically higher (76 percent) compared to Aimovig 70 mg (69...